Spots Global Cancer Trial Database for Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Official Title: Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors

Study ID: NCT02857920

Conditions

Malignant Solid Tumour

Interventions

Bevacizumab

NK immunotherapy

Study Description

Brief Summary: The aim of this study is the safety and efficacy of Bevacizumab plus allogeneic natural killer (NK) immunotherapy to many kinds of recurrent solid tumors.

Detailed Description: By enrolling patients with recurrent solid tumors adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using Bevacizumab and NK cells. The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).